Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells
Authors
Keywords
Apoptosis, Neuroblastoma cells, Cell cycle and cell division, Drug therapy, DNA damage, Chemotherapy, Flow cytometry, Cancer treatment
Journal
PLoS One
Volume 8, Issue 9, Pages e76662
Publisher
Public Library of Science (PLoS)
Online
2013-10-01
DOI
10.1371/journal.pone.0076662
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development of treatment strategies for advanced neuroblastoma
- (2012) Junichi Hara International Journal of Clinical Oncology
- Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer
- (2012) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer
- (2012) Guan Wang et al. PLoS One
- Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
- (2011) Xuelian Xu et al. PLoS One
- Anticancer therapy with checkpoint inhibitors: what, where and when?
- (2011) Michelle D. Garrett et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Neuroblastoma: Therapeutic strategies for a clinical enigma
- (2010) Shakeel Modak et al. CANCER TREATMENT REVIEWS
- Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia
- (2010) C. Xie et al. CLINICAL CANCER RESEARCH
- New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
- (2010) Y. Dai et al. CLINICAL CANCER RESEARCH
- The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
- (2010) Paul A Marks EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells
- (2010) William Brazelle et al. PLoS One
- Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair
- (2009) E. Bolderson et al. CLINICAL CANCER RESEARCH
- Clinical Studies of Histone Deacetylase Inhibitors
- (2009) H. M. Prince et al. CLINICAL CANCER RESEARCH
- Cell cycle kinases as therapeutic targets for cancer
- (2009) Silvia Lapenna et al. NATURE REVIEWS DRUG DISCOVERY
- Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
- (2008) G. Garcia-Manero et al. BLOOD
- Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes
- (2008) V. M. Klimek et al. CLINICAL CANCER RESEARCH
- A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
- (2008) Peter Gimsing et al. EUROPEAN JOURNAL OF HAEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now